Skip to main content
SpringerLink
Log in

Botulinumtoxin-Präparate

  • Chapter
  • First Online:
Botulinumtoxin in der ästhetischen Dermatologie

  • 1598 Accesses

Zusammenfassung

In der ästhetischen Medizin wird ausschließlich Botulinum-Neurotoxin-Serotyp A (BoNT/A) verwendet. In Deutschland sind drei BoNT/A-Präparate für ästhetisch-medizinische Indikationen zugelassen: Azzalure® (Galderma Laboratorium GmbH), Bocouture® (Merz Pharma GmbH & Co. KG) und Vistabel® (Allergan Pharmaceuticals).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Chertow DS1, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR (2006) Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA Nov 22;296(20):2476-2479

    Google Scholar 

  • Fachinfo: Bocouture® (Hersteller: Merz Pharma GmbH & Co. KG), Vistabel® (Hersteller: Allergan Pharmaceuticals) und Azzalure® (Hersteller: Galderma Laboratorium GmbH)

    Google Scholar 

  • Hunt T, Clarke K (2008) Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol 58(3):517–518

    Article  Google Scholar 

  • Imhof M, Podda M, Sommer B (2013) AWMF-Leitlinie „Ästh BTX“/ S1 guideline aesthetic botulinum toxin therapy. German Society for Dermatosurgery; German Society for Dermatology. J Dtsch Dermatol Ges Oct;11(10):e1–13. https://doi.org/10.1111/ddg.12195

  • Pickett A, Mewies M (2009) Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 61(1):149–150

    Article  Google Scholar 

  • Sommer B, Bergfeld D, Sattler G et al (Hrsg) (2015) Botulinumtoxin in der ästhetischen Medizin, 5., aktual. Aufl. Thieme, Stuttgart. https://doi.org/10.1055/b-003-128226

Download references

Author information

Authors and Affiliations

  1. Dermatologie am Luegplatz, Düsseldorf, Deutschland

    Peter Arne Gerber

  2. Privatpraxis Dr. Hilton & Partner, Düsseldorf, Deutschland

    Said Hilton

Authors
  1. Peter Arne Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Said Hilton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Arne Gerber .

Editor information

Editors and Affiliations

  1. Privatpraxis Dr. Hilton & Partner, Düsseldorf, Germany

    Said Hilton

  2. Dermatologie am Luegplatz, Düsseldorf, Germany

    Peter Arne Gerber

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gerber, P.A., Hilton, S. (2020). Botulinumtoxin-Präparate. In: Hilton, S., Gerber, P.A. (eds) Botulinumtoxin in der ästhetischen Dermatologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-58953-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-58953-3_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-58952-6

  • Online ISBN: 978-3-662-58953-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation